NCT00516841 - A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Ovarian CancerPeritoneal Neoplasms

Interventions

DRUG

Volociximab

15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops

Trial Locations (23)

10021

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Medical Center, The Bronx

19111

Fox Chase Cancer Center, Philadelphia

31404

Memorial Health University Medical Center, Savannah

32804

Florida Hospital Cancer Institute, Orlando

40202

James Graham Brown Cancer Center, Louisville

46202

Indiana University, Indianapolis

59101

Billings Clinic (MCMRC network), Billings

60637

University of Chicago, Chicago

73104

Oklahoma University Health Science Center, Oklahoma City

75231

Texas Oncology PA, Presbyterian, Dallas

75246

Mary Crowley Medical Research Center, Dallas

90024

UCLA JCCC Clinical Research Unit, Los Angeles

92123

Sharp Hospital, San Diego

92868-3201

UCI Medical Center, Orange

21231-1000

Johns Hopkins Kimmel Cancer Center, Baltimore

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

T2N4N2

Tom Baker Cancer Center, Calgary

T6G1Z2

Cross Cancer Institute, Edmonton

NGA4L6

London Health Sciences Center, London

H3A 1A1

McGill University Hospital, Montreal